中文摘要：

目的：探讨孤儿核受体-雌激素受体相关受体（ERR）α及雌激素受体（ER）α在子宫内膜癌发生、发展中的作用以及临床应用价值。方法：采用免疫组化法检测35例子宫内膜腺癌组织中ERα和ERRα的表达，评估其与临床病理参数之间的关系。结果：Ⅰ期子宫内膜癌组织中ERα的阳性表达率明显高于Ⅱ-Ⅳ期者（P=0．005）；而ERRα的阳性表达率明显低于Ⅱ～Ⅳ期者（P=0．007）。ERα（＋）和ERRα（-）组中Ⅰ期子宫内膜癌的比例、G1～2级者及肌层浸润深度〈1／2者的数目均明显高于ERα（-）ERRα（＋）组（P=0．000，P=0．031和P=0．022）。结论：ERα可作为子宫内膜癌预后良好的指标，而ERRα可能是子宫内膜癌预后不良的指标，二者联合监测有可能提高临床预测价值。

英文摘要：

Objective： To explore the roles of estrogen receptor-related receptor （ERR）α and estrogen receptor α in endometrial carcinoma and their clinical values. Methods： Thirty-five cases of endometrial carcinoma were examined by immunohistochemistry. Clinicopathologic features including FIGO stage, histological grade, myometrial invasion and nodal metastasis were reviewed. Results： The expression rate of ERα in patients with FIGO stage Ⅰendometrial carcinoma was more than that in stage Ⅱ-Ⅳ （ P = 0. 005 ） ; The expression rate of ERRα in endometrial carcinoma patients at FIGO stage Ⅰ was lower than that at stages Ⅱ -Ⅳ（ P = 0. 007）. The percentage of patients at FIGO stage Ⅰ or with G1-2 or myometrial invasion 〈 1/2 in ERα （ ＋ ） and ERRα （ - ） groups was higher than that in ERα （ - ） and ERRα （ ＋ ） groups （ P = 0. 000, P = 0.031 and P = 0. 022）. Conclusion： ERα may be a biomarker of good prognosis while ERRα may serve as a biomarker of poor prognosis in endometrial carcinoma. The combinative measure of ERα and ERRα may improve the prognostic value.